PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...

Find out how scientists are maximizing retinal organoid effectiveness to sustain critical retinal ganglion cells.

Please provide your email address to receive an email when new articles are posted on . According to Singh, increased availability of anti-VEGF biosimilars will improve patient access and decrease ...

The 2003 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) was held in May in Fort Lauderdale, Florida. The retinal sessions were dominated by reports of new treatments ...

Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...